Evidence map›Paper›PMID 40904941›Full record

ArticleJournal of hematology2025

Does Time Matter From Diagnosis to Induction in Acute Myeloid Leukemia?

Osama Batayneh, Deevyashali Parekh, Margarita Vazquez Almonte, Cristina Hamacher, Angela Gupta, Danielle Passafiume, Michael Sandhu, Carina Hernandez, Safa Afridi, Sanjay Rao Gergal GopalakrishnaRao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Osama BataynehDepartment of Hematology and Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.ORCID https://orcid.org/0000-0001-8131-2441
Deevyashali ParekhDepartment of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Margarita Vazquez AlmonteSUNY Upstate Medical University, Syracuse, NY, USA.
Cristina HamacherDepartment of Internal Medicine, Brown University/Kent Hospital, Providence, RI, USA.
Angela GuptaSUNY Upstate Medical University, Syracuse, NY, USA.
Danielle PassafiumeSUNY Upstate Medical University, Syracuse, NY, USA.
Michael SandhuDepartment of Hematology/Oncology, Montefiore Medical Center, New York City, NY, USA.
Carina HernandezDepartment of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Safa AfridiDepartment of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Sanjay Rao Gergal GopalakrishnaRaoDepartment of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Alyssa CorteseDepartment of Hematology and Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.
Alexandra GoodmanDepartment of Hematology and Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.
Kelsey ChristoSUNY Upstate Medical University, Syracuse, NY, USA.
Josh WallaceSUNY Upstate Medical University, Syracuse, NY, USA.
Teresa GentileDepartment of Hematology and Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While molecular and cytogenetic testing may change prognosis and guide treatment intensity for patients with acute myeloid leukemia (AML), timing from diagnosis to treatment (TDT) on the other hand may impact treatment outcomes and survival. These considerations are sometimes at odds with each other given that molecular studies can take up to 2 weeks to result. Methods: A retrospective cohort analysis was conducted at SUNY Upstate University Hospital to examine the effect of TDT on complete remission (CR) and overall survival (OS). The subjects were at least 18 years old and diagnosed with AML and treated between January 2010 and June 2024. TDT was divided into three categories: chemotherapy induction within 1 - 5, 6 - 10, and 11+ days. Univariate Kaplan-Myer survival analysis and multivariate Cox regression model were performed. Results: A total of 187 patients were included, and 34% (n = 64) were younger than age 60. Patients were classified as 20% (n = 37) favorable, 36% (n = 67) intermediate, and 40% (n = 74) adverse risk, , while 4% risk stratification could not be completed due to missing data. Seventy-two percent (n = 134) had Conclusion: Our retrospective study showed no difference in OS based on TDT groups, which supports clinicians' approach to await on comprehensive AML profiling for an optimal risk stratification at diagnosis and implementing best course of action.

Indexed as

Acute myeloid leukemiaComplete remissionOverall survivalTiming from diagnosis to treatment

Identifiers

PMID40904941
PMCPMC12404120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.